Belgium-based molecular diagnostics firm Biocartis Group has partnered with UK-based medical research charity organisation MRC Technology (MRCT) to develop a new liquid biopsy test for breast cancer.

The test is part of a new agreement between the firms, under which they intend to jointly develop select molecular diagnostic tests that can be used on Biocartis’ fully automated Idylla platform.

MRCT will act as a development contractor for each selected test, and Biocartis will commercialise them under its label.

Biocartis R&D and Alliance Management head Erwin Sablon said: “Building partnerships with third parties to accelerate the expansion of our menu of molecular diagnostic tests is a key element in our strategy.

"MRCT has an experienced team in place and we are confident that together we can successfully develop a range of high-quality tests for the Idylla platform, beginning with this first test for breast cancer."

“MRCT has an experienced team in place and we are confident that together we can successfully develop a range of high-quality tests for the Idylla platform, beginning with this first test for breast cancer.”

The liquid biopsy test is the first diagnostic product under the collaboration and will be designed to monitor resistance to hormone therapy in metastatic breast cancer patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MRCT Diagnostics and Science Foresight director Michael Dalrymple said: “We believe [the test] can impact the way molecular diagnostics for oncology is done today.”

Biocartis liquid biopsy portfolio currently includes three assays for melanoma and colorectal cancer detection, with a fourth assay for lung cancer set to launch in the coming months.


Image: Biocartis’ Idylla platform. Photo: courtesy of Biocartis NV.